Fasenra Misses in Phase 3 For Eosinophilic Esophagitis

AstraZeneca’s blockbuster Fasenra (benralizumab) has stumbled in its quest to become a therapy for eosinophilic esophagitis, failing to hit the clinical target of its dual-primary endpoints in a critical phase 3 trial.
Source: Drug Industry Daily